NVO - Study finds 30% of Wegovy Saxenda users quit within 4 weeks
2024-05-21 14:06:23 ET
More on Novo Nordisk
- The FTC Cracks Down On Novo Nordisk's Ozempic
- Novo Nordisk A/S 2024 Q1 - Results - Earnings Call Presentation
- Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript
- Novo Nordisk unsure when it will meet obesity drug demand: report
- Microcap Mangoceuticals doubles on plan to sell cheap oral GLP-1 weight loss meds